Artivion vs Bioventus
AORT and BVS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AORT and BVS compare
Artivion and Bioventus are about the same size, with market caps of $980M and $924M.
Artivion grew revenue faster over the last twelve months (14.0% versus 3.9% for Bioventus).
Bioventus keeps more of each dollar of sales as profit, with a net margin of 9.8% compared with −3.7% at Artivion.
Bioventus scores higher on the StockData Score (14 against 8 for Artivion), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AORT | BVS |
|---|---|---|
| Size and price | ||
| Market cap | $980M | $924M |
| Share price | $20.10 | $10.99 |
| Change, 1 year | −55.3% | 46.7% |
| Change, 5 years | 6.1% | −21.6% |
| Beta (5Y) | 1.16 | 0.91 |
| Employees | 1,800 | 930 |
| StockData Score | ||
| Total score | 8 | 14 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 3 | 5 (better) |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 13.7× |
| P/S | 2.0× | 1.6× (better) |
| P/B | 2.2× (better) | 3.8× |
| EV/EBITDA | 34.8× | 14.4× (better) |
| P/FCF | – | 10.9× |
| FCF yield | −4.5% | 9.2% (better) |
| Fair value | $15.71 | $16.36 |
| Margin of safety | −28.0% | 32.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.0% (better) | 3.9% |
| Revenue growth, 5Y average | 11.8% | 12.1% (better) |
| Net income growth (TTM) | – | 655% |
| EPS growth (TTM) | – | 627% |
| Profitability | ||
| Gross margin | 63.3% | 68.7% (better) |
| Operating margin | 2.3% | 9.7% (better) |
| Net margin | −3.7% | 9.8% (better) |
| FCF margin | −9.2% | 14.5% (better) |
| Return on equity | −4.0% | 28.2% (better) |
| Return on invested capital | 1.3% | 12.8% (better) |
| Financial health | ||
| Debt / equity | 0.81 (better) | 0.96 |
| Net debt / EBITDA | 8.47 | 2.44 (better) |
| Interest coverage | 0.4× | – |
| Current ratio | 4.42 (better) | 1.68 |
| Altman Z-score | 1.69 | 2.19 (better) |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.77% | −0.31% (better) |
| Shareholder yield | −0.77% | −0.31% (better) |
| Ownership | ||
| Held by institutions | 94.9% | 71.2% |
| Held by insiders | 8.9% | 29.0% |
| Insider net buying, 12 months | −$12.1M | −$181K (better) |
| Short interest, % of float | 7.7% | 5.1% |
Go deeper
- AORT stock overview
- AORT income statement
- AORT valuation and score
- BVS stock overview
- BVS income statement
- BVS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.